Velphoro and Impact on the Oral Cavity and Gut Microbiome

Terminated

• Conditions: Hyperphosphatemia
• Interventions: Drug: Velphoro; Other: saliva collection; Other: Supragingival biofilm collection; Other: stool collection; Other: blood collection

• Registration Number: NCT03409757
• Lead Sponsor: RWTH Aachen University

Brief Summary

This pilot study will be carried out to determine if the regular intake of iron-based Velphoro® by hyperphosphatemia patients influences the microbiome in the oral cavity and/or the gut.

Detailed Description

The aim of this study is to investigate potential changes in the microbiome of the oral cavity and/or gut in patients with hyperphosphatemia following Velphoro® intake for one month. The principal intention of this study is to assess consequences of Velphoro® medication beyond phosphate control. Adherence to the drug might be compromised by e.g. staining of teeth and biofilm after chewing the product more than recommended. Most likely this is a cosmetic problem only and easy to solve by optimizing oral hygiene. The increased level of iron may have an effect on the gut microbiome which could lead to mild diarrhoea. However, the present study will assess, whether the microbiome both oral and gut changes significantly due to some iron bio-availability, although this is expected to be low with sucroferric oxyhydroxide.

The ultimate goal is to improve patient adherence to the drug and to resolve potential safety concerns.

Study Timeline

• Study First Submitted: 2017-12-05
• Study First Submitted QC: 2018-01-17
• Study First Posted: 2018-01-24
• Study Start: 2018-02-28
• Primary Completion: 2020-10-06
• Study Completion: 2020-10-06
• Status Verified: 2020-11
• Last Update Submitted: 2020-11-23
• Last Update Posted: 2020-11-25

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Suffering from hyperphosphatemia
• Current treatment with a stable dose of a non-iron containing phosphate binder,
• No or only parenteral iron application
• Age of ≥ 18 years
• Written informed consent prior to study participation
• The subject is willing and able to follow the procedures outlined in the protocol

Control group:

• Normal renal function
• No hyperphosphatemia
• Age- and sex-matched and oral disease status-matched (dental caries and periodontal disease) in comparison to the hyperphosphatemia group
• Written informed consent prior to study participation
• The subject is willing and able to follow the procedures outlined in the protocol

Exclusion Criteria

• Age less than 18 years
• Currently on oral iron application
• Antibiotic treatment within the last two months
• Severe medical events within the last three months
• Planned surgery for the duration of the sampling
• Acute/chronic gastrointestinal infections
• Smokers
• Oral candidiasis
• Oral cancer
• Pregnant and lactating females
• Haemochromatosis history
• Committed to an institution by legal or regulatory order
• Participation in a parallel interventional clinical trial
• Receipt of an investigational drug within 30 days prior to inclusion into this study
• The subject is mentally or legally incapacitated

Only for the patient group:

• Never got any phosphate binder
• Allergy to Velphoro®
• Celiac disease or any other chronic inflammatory bowel disease
• Previous major surgery in the gastrointestinal tract

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
hemodialysis patients with hyperphosphatemia	Velphoro	* dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool * Velphoro® medication
hemodialysis patients with hyperphosphatemia	Supragingival biofilm collection	* dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool * Velphoro® medication
control group	saliva collection	- dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool
hemodialysis patients with hyperphosphatemia	blood collection	* dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool * Velphoro® medication
hemodialysis patients with hyperphosphatemia	saliva collection	* dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool * Velphoro® medication
control group	stool collection	- dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool
control group	Supragingival biofilm collection	- dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool
hemodialysis patients with hyperphosphatemia	stool collection	* dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool * Velphoro® medication

Primary Outcome Measures

Name	Time	Method
change in relative abundances of iron depending bacterial species within the microbiome from before Velphoro medication to afterwards	4 weeks

Secondary Outcome Measures

Name	Time	Method
Change of distribution of bacterial species within the microbiome from baseline to after Velphoro medication	4 weeks	via diversity measure

Trial Locations

Locations (1)

University Hospital of RWTH Aachen, Department of Medicine II; 🇩🇪 Aachen, Germany